Media release detail page

Allschwil, Switzerland, August 31, 2022

Spexis announces presentation of half-year 2022 financial results and participation at upcoming industry and investor events in September

Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company will hold a live call and webcast to discuss its half-year 2022 financial results and provide a business update on September 6, 2022, 8am ET / 2pm CET.

To participate, please use the following numbers:

France:  +33 (0)1 70 730 3 39

Germany:  +49 (0)69 22222 5197

Italy:   +39 0200638217

Switzerland:  +41 (0)44 580 7279

United Kingdom +44 (0)330 165 4012

United States  +1 646-828-8073

Please dial in approximately 10 minutes prior to the start of the call.  When asked, please provide the name of the event – “Spexis H1 2022 Financial Results and Business Update” – and the following confirmation code: 7688870.

The presentation will also be available via webcast:

• For participants of the conference call: https://www.webcast-eqs.com/spexis20220906/ no-audio (audio via phone, presentation on the web browser)
• Live stream: https://www.webcast-eqs.com/spexis20220906 (audio and presentation on the web browser; for passive participants)

A replay of the call will be available on the Company’s website in the Investor Relations – Calendar section here or via the above link.

In addition, management will participate at the following events in September:

• German Fall Conference (Herbstkonferenz)
  September 5-6, 2022, Frankfurt, Germany

Stephan Wehselau, COO, will give a company presentation on September 6^th at 10:45 AM CET and will also meet with investors.

• Sachs Associates 22^nd Annual Biotech in Europe Forum
  September 21-22, 2022, Basel, Switzerland

Dr. Wager will give a company presentation and meet with investors.

• BioPharm America

September 28-29, 2022, Boston, U.S. (in-person) & October 4-5, 2022 (virtual)

Dr. Wager will participate in this partnering event. Anyone interested in speaking with the company is invited to request a meeting via the PARTNERINGONE^® platform.

For further information please contact:

About Spexis

Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on rare diseases and oncology. For further information, please visit: www.spexisbio.com.

Disclaimer

This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.